CVRx, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $139.8M
- Price
- $5.27
- % Change (Daily % change from the live per-ticker quote feed.)
- -8.19%
- Volume
- 224.0K
Quote data as of 5:23 AM ET
About
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Quick stats
Shares outstanding26.5M
Computed float13.3M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001235912
Websitehttps://www.cvrx.com
AI Summary
AI-generated1mo agominorneutralexecutive changeCVRx Announces Chief Financial Officer Transition
CVRx announced that CFO Jared Oasheim is stepping down to pursue other opportunities after a decade with the company.
Oasheim will remain with CVRx until a successor is appointed and will serve as an advisor through February 2027 to ensure a seamless transition.
The company is initiating a search for a new CFO, while CEO Kevin Hykes praised Oasheim’s role in taking the company public and building its finance organization.